Confronto
GHRP-6 vs. Ipamorelin
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Crescita
Crescita
N. CAS
87616-84-0
170851-70-4
Peso molecolare
873.02 g/mol
711.86 g/mol
Emivita
0.4 h
2 h
Sequenza
His-D-Trp-Ala-Trp-D-Phe-Lys-NH2Aib-His-D-2-Nal-D-Phe-Lys-NH2Meccanismo d'azione
GHRP-6
GHRP-6 is a high-affinity agonist of the growth-hormone secretagogue receptor 1a (GHSR-1a) — the same receptor later shown to bind the endogenous hormone ghrelin. The identification of GHRP-6 as a pharmacological anchor led to cloning of GHSR in 1996 and the discovery of ghrelin itself in 1999. GHRP-6 stimulates pituitary GH secretion via a pathway independent of GHRH and can be combined synergistically with GHRH. Via GHSR in the hypothalamus it additionally activates NPY/AgRP neurons, producing an orexigenic (appetite-stimulating) effect in animal models.
Ipamorelin
Ipamorelin is a selective agonist at the GH secretagogue receptor (GHSR-1a). Compared to GHRP-2 and GHRP-6 its selectivity for the growth-hormone axis is higher; ACTH, cortisol and prolactin are not significantly stimulated in clinical studies. This selectivity was the main reason for its development over older GHRPs.
Base di evidenze
Evidenza più alta
Studio sull'uomo
RCT sull'uomo
Studi
4
4
di cui sull'uomo
2
3
Effetti registrati
4
3
Contraddizioni aperte
1
1
Eventi avversi documentati
2
1
Stato legale
Voci complete
Frequently asked questions
- What is the difference between GHRP-6 and Ipamorelin?
- GHRP-6 is classified as "Crescita", while Ipamorelin is classified as "Crescita". GHRP-6: Synthetic hexapeptide that founded the class of growth-hormone-releasing peptides (GHRPs). Cyril Bowers identified GHRP-6 in the late 1970s as the first orally and parenterally active GH secretagogue with no structural similarity to GHRH. Never approved as a medicine; downstream analogs (GHRP-2, hexarelin, ipamorelin) were pursued clinically. Ipamorelin: Synthetic pentapeptide and selective growth-hormone secretagogue. Developed at Novo Nordisk in the 1990s as a pentapeptide GHRP successor; clinical development was discontinued after phase 2 (post-operative ileus). This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, GHRP-6 or Ipamorelin?
- The highest available evidence level is "Studio sull'uomo" for GHRP-6 and "RCT sull'uomo" for Ipamorelin. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of GHRP-6 and Ipamorelin in Germany and the United States?
- Germania: GHRP-6 — Non approvato, Ipamorelin — Non approvato. Stati Uniti: GHRP-6 — Non approvato, Ipamorelin — Non approvato. These are factual summaries with source and review date on the individual pages.